From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA accepts for NDA investigational hypertension drug

from Pharmacy Times

The FDA has accepted the new drug application for EZR-201, an investigational product from Ezra Innovations for the treatment of hypertension and heart failure. EZR-201 combines an angiotensin receptor blocker, valsartan, with Rubireten delivery technology. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063